Core Insights - Evogene Ltd. will release its financial results for Q2 2024 on August 22, 2024, followed by a conference call at 9:00 AM ET [1] - The company focuses on leveraging big data and artificial intelligence to enhance life-science product development [2] Company Overview - Evogene Ltd. is a computational biology company aiming to revolutionize life-science product discovery and development through advanced technologies [2] - The company has established three unique tech-engines: MicroBoost AI, ChemPass AI, and GeneRator AI, each targeting different core components for product development [3] Subsidiaries and Focus Areas - Biomica Ltd. focuses on microbiome-based therapeutics for human disorders using MicroBoost AI [3] - Lavie Bio Ltd. develops microbiome-based ag-biologicals, also powered by MicroBoost AI [3] - AgPlenus Ltd. is dedicated to next-generation agricultural chemicals for sustainable crop protection using ChemPass AI [3] - Casterra Ag Ltd. markets high-yield castor seed varieties for biofuel and other industries, utilizing GeneRator AI [3]

Mr. Yoash Zohar, CEO of Casterra states: "Current castor yields from the harvest in Brazil show an impressive improvement in our production capabilities. I am very proud of our professional team, which in past months invested, and keeps investing, time and efforts working closely with our subcontractors to ensure the best agricultural practices and crop performance, to produce Casterra's high quality castor seeds. We also expect to see such positive performance in our African territories where the majority ...

Company Overview - Evogene Ltd. is a computational biology company focused on revolutionizing life-science-based product development through big data and artificial intelligence, aiming to enhance success rates while reducing development time and costs [3][10] - The company operates through five subsidiaries, each leveraging unique tech engines for product development [4][5] Reverse Share Split - A reverse share split at a ratio of 1-for-10 was approved by shareholders and is set to be implemented after market close on July 24, 2024 [10] - Post-split, the number of issued and outstanding Ordinary Shares will decrease from approximately 50,790,000 to about 5,079,000 [4][10] - The company's registered share capital will remain at NIS 3,000,000 but will be divided into 15,000,000 Ordinary Shares with a par value of NIS 0.2 each [4][10] Shareholder Impact - No fractional Ordinary Shares will be issued; fractional shares will be rounded to the nearest whole share, with no cash payments for fractional shares [2] - Proportionate adjustments will be made to the number of shares issuable upon the exercise of outstanding options and Restricted Share Units (RSUs) [2]

Industry Overview - Winter wheat is a crucial crop in North America and globally, contributing significantly to the agricultural economy and food supply, with the US expected to produce about 1.28 billion bushels in 2024, valued between $5-$10 billion annually [1][7] - The US soybean market size is estimated at approximately $56.2 billion in 2024, indicating substantial market potential for agricultural innovations [2] Company Overview - Lavie Bio is focused on enhancing crop productivity and sustainability through its product Yalos™, which has shown improved early vigor, biomass, root and shoot development, nutrient availability, and feed quality in winter wheat during field trials [7][8] - The company aims to expand Yalos™ into other key crops, such as soybean and canola, with ongoing field trials and an expected commercial launch in 2025 [2][8] - Lavie Bio utilizes a proprietary computational predictive platform, the BDD platform, powered by Evogene's MicroBoost AI technology, to discover and develop bio-stimulant and bio-pesticide products [8][9] Strategic Goals - Lavie Bio's strategy includes consistently introducing innovative ag-biological products to the market while expanding existing products to more crops and regions, reinforcing its commitment to advancing agricultural productivity and sustainability globally [8] - The company aims for Yalos™ to become a leading solution for growers in all major field crops, addressing key growth challenges and enhancing plant health and yield [8]

Company Overview - Casterra, a wholly owned subsidiary of Evogene, specializes in developing castor seed varieties for bio-based industrial applications, including biofuels and biopolymers [4] - The company utilizes advanced breeding methods and Evogene's GeneRator AI tech-engine to enhance plant genomics and enable sustainable production of castor beans [4][6] Recent Developments - Casterra has received an additional order for castor seeds, reflecting confidence in its capabilities and products, with expectations to complete the order by Q4 2024 [1] - The company anticipates recognizing approximately $8.4 million in revenue from castor seed orders in the second half of 2024, due to a price adjustment related to late deliveries [1] Market Insights - The global biodiesel market was valued at $36.48 billion in 2022 and is projected to reach around $79.12 billion by 2032, growing at a CAGR of 8.1% from 2023 to 2032 [2] - Biofuels, including castor oil, are gaining traction as renewable and biodegradable alternatives to conventional fuels, with castor oil being compliant with stringent European regulations [2][3] Product Characteristics - Casterra's high oil-yielding castor varieties are designed for large-scale farming on marginal soils in semi-arid conditions, positioning them as a sustainable feedstock for the biofuel industry without competing with food crops [3]

Title: Preliminary results from a First-in-Human (FIH), open-label Phase 1 study with BMC128, a rationally designed live bacterial consortium, in combination with nivolumab. Session Type: Poster Session Abstract Number: 8631 Date and Time: June 3, 2024, 1:30 PM – 4:30 PM (CDT) Key observations from the study include: With these encouraging early results, it is important to note that the study remains ongoing. Further data will become available and analyzed through the next few months to gain a deeper unders ...

Conference call and webcast: today, May 23, 2024, 9:00 am ET Financial and Business Highlights: REHOVOT, Israel, May 23, 2024 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize the development of life-science-based products, today announced its financial results for the first quarter period ended March 31, 2024. Mr. Ofer Haviv, Evogene's President and CEO, stated: "Evogene's mission is to direct and accelerate the development of life-sci ...

Company Overview - Casterra Ag Ltd. is an integrated solutions company focused on the cultivation of castor for bio-based industrial applications, including biofuels and biopolymers [3] - The company has developed a broad collection of over 300 castor lines from 40 different geographic and climatic regions, enhancing its genetic assets [3] - Casterra employs advanced breeding methods and utilizes Evogene's GeneRator AI tech engine to enable efficient and sustainable industrial-scale production of castor beans [3] Strategic Partnerships - Casterra is expanding partnerships with existing and new seed producers to strengthen production capabilities and meet the dynamic needs of customers and markets globally [2] - This proactive commitment aims to mitigate potential production risks and establish a reliable seed production infrastructure [2] Technological Innovation - Casterra utilizes Evogene's GeneRator AI tech engine, which is part of a suite of technologies aimed at revolutionizing life-science-based product development [4] - The tech engine leverages Big Data and Artificial Intelligence to enhance the discovery and development of genetic elements for agricultural applications [4][5] Market Position - Casterra is positioning itself as a leading company in providing comprehensive solutions for the commercial cultivation of castor plants specifically for the biofuel industry [2]

Preliminary data from Biomica's Phase 1 study of BMC128 will be showcased at the conference REHOVOT, Israel, April 16, 2024 /PRNewswire/ -- Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), today announced that it will present preliminary data from its Phase 1 study of BMC128, in combination with immune checkpoint inhibitor (ICI) immunotherapy, in refractory patients with either non-small ...

The pre-clinical work was led by Prof. Yehuda Ringel, Biomica's Co-Founder and CSO, in collaboration with the lab of Prof. Kara Gross Margolis, at the NYU Grossman School of Medicine. In the studies, Biomica tested two candidate therapeutic consortia of live bacterial strains, BMC426 and BMC427. Treatment with these drug candidates effectively reduced visceral pain, a major symptom of IBS. Presentation Details: Session Type: Research ForumSession Title: Gut Instincts: Exploring the Interplay of the Microbio ...